Aspen Pharmacare Holdings Ltd. (APNHY,APN.JO), on Monday announced that, through its wholly owned subsidiary Aspen Global Inc., it has entered into binding agreements to sell its equity interests and intellectual property assets in Australia, New Zealand and other Asia-Pacific markets excluding China to BGH Capital Pty Ltd via two special purpose vehicles.
The transaction carries an unadjusted value of AUD 2.37 billion, or ZAR 26.48 billion.
The transaction involves the sale of Aspen APAC operations in Australia, New Zealand, Hong Kong, Malaysia, Taiwan and the Philippines, including relevant intellectual property commercialised in the region.
On a cash- and debt-free basis, implies an enterprise value to normalised full year 2025 EBITDA multiple of about 11x.
Aspen said the APAC business was not actively being marketed for sale, but the boards evaluated an unsolicited proposal from BGH Capital and subsequently invited a binding offer.
Following a detailed assessment, the boards concluded that the transaction provides compelling value for shareholders.
The company said that the net proceeds are expected to be used primarily to reduce debt and optimise the group's capital structure, leading to lower financing costs, a simplified lender base, and increased focus on strategic growth priorities.
On Friday, Aspen Pharmacare 0.46% lesser at ZAc 9,450 on the Johannesburg Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.